Iambic Therapeutics: Inside the Company Advancing and Accelerating AI in Drug Development

How does a techbio company get to clinic faster and scale a platform business? In this discussion moderated by Freeflow’s David Fleck and Kevin Barrett, Iambic CEO and Cofounder Tom Miller shares how Iambic pairs rapid clinical execution with a platform + partnership engine — plus the clinical and corporate milestones that are driving momentum today.

This session is designed for founders, product and science leads, and investors who want a first-hand view into a world leading example of how the combination of compute and multi-science approaches is generating real-world impact faster than ever.